IL105495A0 - Pharmaceuticals - Google Patents
PharmaceuticalsInfo
- Publication number
- IL105495A0 IL105495A0 IL105495A IL10549593A IL105495A0 IL 105495 A0 IL105495 A0 IL 105495A0 IL 105495 A IL105495 A IL 105495A IL 10549593 A IL10549593 A IL 10549593A IL 105495 A0 IL105495 A0 IL 105495A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceuticals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929208859A GB9208859D0 (en) | 1992-04-24 | 1992-04-24 | Compounds |
GB929208871A GB9208871D0 (en) | 1992-04-24 | 1992-04-24 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL105495A0 true IL105495A0 (en) | 1993-08-18 |
Family
ID=26300767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL105495A IL105495A0 (en) | 1992-04-24 | 1993-04-22 | Pharmaceuticals |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0637303A1 (fr) |
JP (1) | JPH07506104A (fr) |
KR (1) | KR950701330A (fr) |
CN (1) | CN1083055A (fr) |
AU (1) | AU3959893A (fr) |
CA (1) | CA2133984A1 (fr) |
IL (1) | IL105495A0 (fr) |
MA (1) | MA22880A1 (fr) |
SI (1) | SI9300217A (fr) |
WO (1) | WO1993022302A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9321811D0 (en) * | 1993-10-22 | 1993-12-15 | Smithkline Beecham Plc | Pharmaceuticals |
ES2239766T3 (es) * | 1995-01-23 | 2005-10-01 | Daiichi Suntory Pharma Co., Ltd. | Alivio o remedio para sintomas causados por enfermedades isquemicas y compuestos de fenilpiperidina utilizados para ello. |
US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
AU1600599A (en) | 1998-02-27 | 1999-09-15 | Warner-Lambert Company | Heterocyclic substituted aniline calcium channel blockers |
US6166052A (en) | 1998-03-11 | 2000-12-26 | Warner-Lambert Company | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
US7417040B2 (en) | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US20210309623A1 (en) * | 2020-03-11 | 2021-10-07 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1299247A (en) * | 1970-06-22 | 1972-12-13 | Labaz | Benzofuran derivatives and process for preparing the same |
GB2078217B (en) * | 1980-06-14 | 1984-01-11 | Beecham Group Ltd | Phenolic ethers their preparation and use |
JPS58113140A (ja) * | 1981-12-14 | 1983-07-05 | シンテツクス(ユ−・エス・エイ)インコ−ポレイテツド | ナフトキシアルキル化合物、その製造法およびそれからなる抗炎症剤 |
US4851423A (en) * | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
DE3706585A1 (de) * | 1987-02-25 | 1988-09-08 | Schering Ag | Aryl- und aryloxy-substituierte tert.-alkylenamine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
CA2020888A1 (fr) * | 1989-07-27 | 1991-01-28 | Philippe Guerry | Derives d'aminoalkoxybenzene substitues |
TW199153B (fr) * | 1990-08-07 | 1993-02-01 | Dtsuka Seiyaku Kk |
-
1993
- 1993-04-15 CA CA002133984A patent/CA2133984A1/fr not_active Abandoned
- 1993-04-15 JP JP5519026A patent/JPH07506104A/ja active Pending
- 1993-04-15 WO PCT/GB1993/000801 patent/WO1993022302A1/fr not_active Application Discontinuation
- 1993-04-15 AU AU39598/93A patent/AU3959893A/en not_active Abandoned
- 1993-04-15 EP EP93909052A patent/EP0637303A1/fr not_active Withdrawn
- 1993-04-15 KR KR1019940703826A patent/KR950701330A/ko not_active Application Discontinuation
- 1993-04-22 MA MA23173A patent/MA22880A1/fr unknown
- 1993-04-22 IL IL105495A patent/IL105495A0/xx unknown
- 1993-04-23 CN CN93106361A patent/CN1083055A/zh active Pending
- 1993-04-23 SI SI9300217A patent/SI9300217A/sl unknown
Also Published As
Publication number | Publication date |
---|---|
AU3959893A (en) | 1993-11-29 |
JPH07506104A (ja) | 1995-07-06 |
EP0637303A1 (fr) | 1995-02-08 |
CA2133984A1 (fr) | 1993-11-11 |
MA22880A1 (fr) | 1993-12-31 |
WO1993022302A1 (fr) | 1993-11-11 |
SI9300217A (sl) | 1993-12-31 |
KR950701330A (ko) | 1995-03-23 |
CN1083055A (zh) | 1994-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP9300494A0 (en) | Pharmaceuticals | |
GB9221468D0 (en) | Pharmaceuticals | |
GB9204565D0 (en) | Pharmaceuticals | |
GB9219163D0 (en) | Pharmaceuticals | |
GB9205917D0 (en) | Pharmaceuticals | |
GB9214184D0 (en) | Pharmaceuticals | |
IL105495A0 (en) | Pharmaceuticals | |
GB9201961D0 (en) | Pharmaceuticals | |
GB9220585D0 (en) | Pharmaceuticals | |
GB9208321D0 (en) | Pharmaceuticals | |
GB9205428D0 (en) | Pharmaceuticals | |
GB9203977D0 (en) | Pharmaceuticals | |
GB9211978D0 (en) | Pharmaceuticals | |
GB9211926D0 (en) | Pharmaceuticals | |
GB9211925D0 (en) | Pharmaceuticals | |
GB9211082D0 (en) | Pharmaceuticals | |
GB9211072D0 (en) | Pharmaceuticals | |
GB9208434D0 (en) | Pharmaceuticals | |
GB9214399D0 (en) | Pharmaceuticals | |
GB9207820D0 (en) | Pharmaceuticals | |
GB9207414D0 (en) | Pharmaceuticals | |
GB9206075D0 (en) | Pharmaceuticals | |
GB9205918D0 (en) | Pharmaceuticals | |
GB9215499D0 (en) | Pharmaceuticals | |
GB9220508D0 (en) | Pharmaceuticals |